Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (191-200 of 252) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, et al.
JNCI Cancer Spectrum|April 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD databaseHideaki Bando, Yuriko Takeda, Toshihiro Misumi, et al.
Targeted Oncology|March 1, 2024
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GToshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, et al.
Clinical Colorectal Cancer|August 15, 2016
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102Satoshi Hamauchi, Kentaro Yamazaki, Toshiki Masuishi, et al.
Cancer Science|November 28, 2021
DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsyMasaaki Miyo, Takeshi Kato, Yoshiaki Nakamura, et al.
Frontiers in Cellular and Infection Microbiology|October 3, 2022
Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversitiesShunsuke A Sakai, Masato Aoshima, Kentaro Sawada, et al.
JCO Precision Oncology|August 11, 2022
Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric CancerKaori Hino, Tomohiro Nishina, Takeshi Kajiwara, et al.
Nature Medicine|January 16, 2023
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancerDaisuke Kotani, Eiji Oki, Yoshiaki Nakamura, et al.
Clinical Colorectal Cancer|September 28, 2016
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective ComparisonToshiki Masuishi, Hiroya Taniguchi, Satoshi Hamauchi, et al.
Oncology|September 4, 2017
Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal CancerAzusa Komori, Hiroya Taniguchi, Satoshi Hamauchi, et al.
Pageof 26

Showing results (191-200 of 252) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, et al.
JNCI Cancer Spectrum|April 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD databaseHideaki Bando, Yuriko Takeda, Toshihiro Misumi, et al.
Targeted Oncology|March 1, 2024
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GToshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, et al.
Clinical Colorectal Cancer|August 15, 2016
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102Satoshi Hamauchi, Kentaro Yamazaki, Toshiki Masuishi, et al.
Cancer Science|November 28, 2021
DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsyMasaaki Miyo, Takeshi Kato, Yoshiaki Nakamura, et al.
Frontiers in Cellular and Infection Microbiology|October 3, 2022
Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversitiesShunsuke A Sakai, Masato Aoshima, Kentaro Sawada, et al.
JCO Precision Oncology|August 11, 2022
Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric CancerKaori Hino, Tomohiro Nishina, Takeshi Kajiwara, et al.
Nature Medicine|January 16, 2023
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancerDaisuke Kotani, Eiji Oki, Yoshiaki Nakamura, et al.
Clinical Colorectal Cancer|September 28, 2016
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective ComparisonToshiki Masuishi, Hiroya Taniguchi, Satoshi Hamauchi, et al.
Oncology|September 4, 2017
Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal CancerAzusa Komori, Hiroya Taniguchi, Satoshi Hamauchi, et al.
Pageof 26